TY - JOUR
T1 - Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply
AU - Henry, David
AU - McGettigan, Patricia
PY - 2007/2/14
Y1 - 2007/2/14
N2 - In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16%. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.
AB - In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16%. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.
UR - http://www.scopus.com/inward/record.url?scp=33846953546&partnerID=8YFLogxK
U2 - 10.1001/jama.297.6.587
DO - 10.1001/jama.297.6.587
M3 - Letter
AN - SCOPUS:33846953546
VL - 297
SP - 587
EP - 588
JO - Journal of the American Medical Association
JF - Journal of the American Medical Association
SN - 0098-7484
IS - 6
ER -